Clinical trials: Motor Response Time
Parkinson's Disease
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
- Trial name
- NCT00199368
- Testing
- Istradefylline ( KW-6002)
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- Kyowa Kirin, Inc.
Parkinson's Disease
Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens
The primary objective is to assess the effect of a single dose of two experimental levodopa/carbidopa/entacapone (L/C/E) treatment regimens versus standard L/C/E treatment regimen in Parkinson's disease (PD) patients with…
- Trial name
- PARTEST (NCT01296464)
- Testing
- Carbidopa
- Where
- 5 sites in Finland, Sweden
- Volunteers
- 27 people
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson's Disease
A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
To establish the efficacy of 10, 20 and 40 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
- Trial name
- NCT00199420
- Testing
- Istradefylline (KW-6002)
- Where
- 2 sites in United States
- Volunteers
- 580 people
- Sponsor
- Kyowa Kirin, Inc.
Parkinson's Disease
12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated…
- Trial name
- NCT00456586
- Testing
- KW-6002 (istradefylline)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Kyowa Kirin, Inc.
Parkinson's Disease
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
A 12-week, multicenter, double-blind, randomized study designed to evaluate the safety and efficacy of 20 and 60 mg/day istradefylline compared with placebo in subjects with OFF-time phenomena and advanced Parkinson's disease…
- Trial name
- NCT00456794
- Testing
- Istradefylline (KW-6002)
- Where
- United States
- Volunteers
- 325 people
- Sponsor
- Kyowa Kirin, Inc.
Parkinson's Disease
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
To establish the efficacy of a 20 mg/day dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
- Trial name
- NCT00199407
- Testing
- Istradefylline (KW-6002)
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Kyowa Kirin, Inc.